The CDMO’s latest investment will boost capacity at its Charles City, IA facility by 40%, underscoring Cambrex’s focus on ...

The agency’s decision to conceal drug names on inspection reports has prevented doctors, pharmacists and patients from ...

Though riddled with inconsistencies, the report indicates hundreds of thousands of arrests are still being made for marijuana ...

Cambrex will invest $120M to expand U.S. drug manufacturing, boosting API capacity at its Iowa site and adding jobs amid ...

In a press release, Cambrex CEO Thomas Loewald calls the Charles City site the largest independent API manufacturing facility ...

The Charles City facility, situated on a 45-acre site, manufactures a broad range of APIs and pharmaceutical intermediates, ...

Success with a smart VF is less about the screens and more about how people interact with the data and each other.

We wanted to know where a widely used prescription drug that treats high cholesterol was manufactured and whether the factory ...

Lonza Group said its third-quarter performance was strong, with a return to growth at its capsules-and-health ingredients unit, and that it is on track to achieve full-year guidance for its core ...

Swiss contract drug manufacturer Lonza confirmed its full-year guidance on Thursday after a strong third quarter for its main contract development and manufacturing organization (CDMO) business.

It's the latest in a string of announcements by pharmaceutical manufacturers to build or expand operations in Virginia.

Throughout 2025, drugmakers of all stripes have collectively poured billions of dollars into U.S. manufacturing investments.